AspenBio Pharma shares rise on start of clinical trials
AspenBio Pharma, Inc. (Nasdaq:APPY) announced Thursday it had begun independent clinical trials for its AppyScore appendicitis diagnostic test. The biopharmaceutical company’s stock moved up 11% Thursday to $6.28 with volume well above 580,000 shares. The Castle Rock, Colo.-based company said it expects the Food and Drug Administration trial to be finished within four to six months. If approved, AppyScore will be the first blood-based diagnostic test for human appendicitis, CEO Richard Donnelly said in a statement.
For detailed price information and recent news stories about AspenBio Pharma, Inc., click APPY.
